dc.contributorSilva, José Edson Paz da
dc.creatorBauer, Renan Nolibos
dc.date.accessioned2015-11-18T13:36:23Z
dc.date.accessioned2019-05-24T20:35:45Z
dc.date.available2015-11-18T13:36:23Z
dc.date.available2019-05-24T20:35:45Z
dc.date.created2015-11-18T13:36:23Z
dc.date.issued2005-06-17
dc.identifierhttp://repositorio.ufsm.br/handle/1/1150
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/2842199
dc.description.abstractThe antiphospholipid syndrome (APS) is currently recognized as the main cause of acquired hipercoagulability. The APS can be divided in two categories: Primary APS (PAPS), which occurs in patients without clinical evidences of another associated illness, and Secondary APS (SAPS), that it occurs in association with other illnesses. The main related pathology to the SAPS is the Systemic Lupus Erythematosus. The patientes with APS present venous or arterial thrombosis, being able to attack any sanguine vase in different places of the organism. Of this form, the diagnosis of syndrome interests to the diverse specialties. The diagnosis of the APS require the presence of, at the very least, one of clinical criteria and one of the laboratory criteria. The laboratory criteria are based in the presence of two antiphospholipid antibodies: the anticardiolipin antibodies and the lupus anticoagulant. The mecanism for which the patientes with APS present a bigger trend to the thrombotics events still are not total described. Moreover, doesn´t have a consensus on which is the best therapeutical option and ideal time of treatment.
dc.publisherUniversidade Federal de Santa Maria
dc.publisherCentro de Ciências da Saúde
dc.rightsAcesso Aberto
dc.subjectSíndrome antifosfolípide
dc.subjectAnticorpos anticardiolipina
dc.subjectAnticoagulante lúpico
dc.titleSíndrome antifosfolípide: estudo contemporâneo de um tema relacionado a diversas especialidades
dc.typeTrabalho de Conclusão de Curso de Especialização


Este ítem pertenece a la siguiente institución